GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Olink Holding AB (NAS:OLK) » Definitions » Loans Receivable

Olink Holding AB (Olink Holding AB) Loans Receivable : $0.0 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Olink Holding AB Loans Receivable?

Olink Holding AB's Loans Receivable for the quarter that ended in Dec. 2023 was $0.0 Mil.


Olink Holding AB Loans Receivable Historical Data

The historical data trend for Olink Holding AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olink Holding AB Loans Receivable Chart

Olink Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
- - - - -

Olink Holding AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Olink Holding AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Olink Holding AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Olink Holding AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Olink Holding AB (Olink Holding AB) Business Description

Traded in Other Exchanges
Address
Uppsala Science Park, Uppsala, SWE, SE-75183
Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation. It has two segments including Kit and Services. It derives revenues from Sweden, the Americas, China, EMEA (Excluding Sweden) Japan, and other regions.